3.98 0.06 (1.53%) | 12-01 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 5.18 ![]() |
1-year : | 6.05 ![]() |
Resists | First : | 4.44 ![]() |
Second : | 5.18 ![]() |
Pivot price | 3.76 ![]() |
|||
Supports | First : | 3.86 ![]() |
Second : | 3.5 ![]() |
MAs | MA(5) : | 3.81 ![]() |
MA(20) : | 3.82 ![]() |
MA(100) : | 4.49 ![]() |
MA(250) : | 4.23 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 65.2 ![]() |
D(3) : | 47.8 ![]() |
RSI | RSI(14): 55 ![]() |
|||
52-week | High : | 6.69 | Low : | 3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XBIT ] has closed below upper band by 9.0%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 3.99 - 4.01 | 4.01 - 4.03 |
Low: | 3.71 - 3.73 | 3.73 - 3.75 |
Close: | 3.95 - 3.98 | 3.98 - 4.01 |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Sat, 11 Nov 2023
XBiotech (NASDAQ:XBIT) Coverage Initiated by Analysts at ... - Defense World
Sat, 16 Sep 2023
Individual investors account for 50% of XBiotech Inc.'s (NASDAQ ... - Yahoo Finance
Wed, 23 Aug 2023
Biotechs are Accelerating Drug Discovery by Repurposing Platforms ... - Nasdaq
Wed, 11 May 2022
Understanding Small Cap Stocks | Financial Literacy - Investment U
Wed, 02 Feb 2022
J&J to record $610 mln charge related to skin disease drug - Reuters
Wed, 28 Oct 2020
5 Ben Graham Lost Formula Stocks With High Financial Strength - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 30 (M) |
Held by Insiders | 1.98e+007 (%) |
Held by Institutions | 35.1 (%) |
Shares Short | 277 (K) |
Shares Short P.Month | 0 (K) |
EPS | -3.533e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -12 % |
Return on Assets (ttm) | 361.6 % |
Return on Equity (ttm) | -9.7 % |
Qtrly Rev. Growth | 300000 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -7.12 |
EBITDA (p.s.) | 2.41727e+006 |
Qtrly Earnings Growth | -0.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -18 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.56 |
Price to Cash Flow | 0.75 |
Dividend | 0 |
Forward Dividend | 294470 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |